Huazhong University of Science and Technology Overview

Trial Radar AI Insights

Huazhong University of Science and Technology

Huazhong University of Science and Technology (HUST) leads clinical research in China as a premier public university, driving innovative trials in oncology, metabolic disorders, and infectious diseases that enhance treatment options for patients worldwide. Its extensive portfolio, including over 188 lead-sponsored trials, underscores a commitment to advancing evidence-based medicine, particularly benefiting participants in Asia through collaborations with top hospitals. HUST's patient-first approach integrates cutting-edge technology, such as artificial intelligence in diagnostics, to improve trial accessibility and outcomes.

• Institution Profile: Founded 1952 · Wuhan, China · Public · hust.edu.cn
• Therapeutic Strengths: Oncology, diabetes and metabolic diseases, cardiovascular diseases
• Research standing: Ranked among China's top 10 universities for scientific impact; recipient of multiple national innovation awards, including in medical engineering
• Partnerships: Collaborations with Tongji Hospital and Wuhan Union Hospital for trial execution; affiliations with State Key Laboratories in advanced materials and digital manufacturing to support medical device trials

Clinical Research Infrastructure

HUST maintains a robust clinical research ecosystem anchored in Wuhan, leveraging its affiliated hospitals and specialized labs to conduct trials efficiently. The university's infrastructure facilitates seamless integration of basic science and clinical application, enabling rapid progression from preclinical studies to patient enrollment in multicenter trials across China. Key affiliates include major teaching hospitals that serve as primary sites, ensuring high-quality data collection and diverse participant recruitment.

• Hospitals & Medical Centers: Flagship sites include Tongji Hospital and Wuhan Union Hospital, both high-volume centers for oncology and cardiovascular trials; Huazhong University of Science and Technology Hospital supports interventional studies in metabolic conditions
• Specialty Institutes & Research Facilities: State Key Laboratory of Advanced Electromagnetic Engineering and Technology for device-based trials; centers focused on digital health and laser applications in diagnostics

Key Specialties and Therapeutic Focus

HUST excels in oncology, prioritizing conditions like bladder cancer and cervical cancer through targeted interventions that address high-burden diseases in China. The university also leads in diabetes management and cardiovascular health, employing a mix of pharmacological and behavioral therapies to tackle chronic conditions affecting millions. Therapeutic modalities span drugs (e.g., Huaier granule for cancer), diagnostic tests (e.g., endoscopic ultrasound), and devices, with artificial intelligence enhancing precision in areas like fine-needle biopsy for submucosal tumors.

• Primary focus areas (prioritized by expertise and reputation):
• Oncology: Targets non-muscle-invasive bladder cancer and gastrointestinal stromal tumors; uses small molecules and biologics for improved survival rates
• Metabolic and endocrine disorders: Focuses on type 2 diabetes mellitus; incorporates dietary supplements like vitamin D and prebiotics to modulate gut microbiota
• Infectious and respiratory diseases: Addresses antibiotic prescribing for acute respiratory infections; employs behavioral interventions and radiation therapies
• Therapeutic modalities employed: Drugs (29 trials), devices (10 trials), and dietary supplements (16 trials); emphasis on AI-driven diagnostics and endoscopic procedures
• Leading specialists and their credentials: Experts in oncology from Tongji Hospital, including professors with National Natural Science Foundation grants; cardiologists affiliated with Wuhan Union Hospital holding international board certifications
• Notable treatment breakthroughs and clinical outcomes: Huaier granule trials show reduced recurrence in bladder cancer patients; vitamin D supplementation linked to better glycemic control in diabetes cohorts, with enrollment exceeding 10,000 participants

Huazhong University of Science and Technology Clinical Trials Landscape

Trial StatisticsApply Below Filters

Huazhong University of Science and Technology sponsors 45 active trials as lead or collaborator, with 25 actively recruiting and focusing primarily on adult and older adult participants across 47 locations in China. Total enrollment reaches 180,432 patients, averaging over 4,000 per trial, predominantly in interventional studies (31 of 45) targeting oncology and metabolic diseases at sites like Tongji Hospital. Phase distribution leans toward phase 4 (5 trials) and unphased (19 trials), with a balanced sex distribution favoring all genders and key interventions like drugs and dietary supplements driving enrollment in high-impact conditions such as bladder cancer.

Key Clinical Trial Updates

Recent updates include two trials modified last month, reflecting ongoing refinements in AI-integrated diagnostics for depression and DLBCL. Interim analyses from phase 3 oncology studies suggest promising efficacy in reducing delirium incidence, with primary completions expected in early 2026. Upcoming milestones involve regulatory submissions for vitamin D-based diabetes interventions, alongside breakthrough approvals for endoscopic ultrasound techniques in gastrointestinal tumors as of mid-2025.

Trial Innovation

HUST incorporates artificial intelligence in trial designs for real-time data analysis, particularly in fine-needle biopsy and gut microbiota studies, enhancing accuracy and patient-centric outcomes. Decentralized elements appear in behavioral interventions for antibiotic prescribing, utilizing remote monitoring via digital health tools. The university leverages real-world evidence from large-scale observational trials (14 active) to inform adaptive protocols, positioning it competitively in China's evolving clinical landscape.

Clinical Trial Participation Guide

Trial Radar's participation assistant simplifies the process: use Simplify to summarize trial details, preview steps with What to Expect, and confirm eligibility via Check Eligibility for HUST studies. Access the Contacts & Locations tab to view site-specific information in China and connect directly with study teams at affiliates like Tongji Hospital.

Explore Huazhong University of Science and Technology clinical trials

Explore 50 of 82 potential opportunities.